期刊文献+

葡萄糖腹膜透析液对人腹膜间皮细胞线粒体活性氧的影响 被引量:1

The effect of mitochondrial reactive oxygen species production in human peritoneal mesothelial cells exposed to glucosebased peritoneal dialysis fluids
下载PDF
导出
摘要 目的观察不同浓度葡萄糖腹膜透析液对人腹膜间皮细胞线粒体活性氧(ROS)的影响。方法体外培养人腹膜间皮细胞株第5至10代(HMr SV5,DMEM/F12培养基含10%胎牛血清)用于实验研究。MTT检测细胞活力,实验分为7组:对照组、1.5%Dextrose组、2.5%Dextrose组、4.25%Dextrose组、线粒体呼吸链复合酶Ⅰ抑制剂Rotenone组(5μM)、线粒体呼吸链复合酶Ⅱ抑制剂Thenoyltrifluoroacetone(TTFA)组(5μM)、线粒体呼吸链复合酶Ⅲ抑制剂Antimycin A组(100μg/ml),应用流式细胞仪检测总线粒体、呼吸线粒体、超氧化线粒体。结果各组作用12h,1.5%Dextrose、2.5%Dextrose、4.25%Dextrose、Rotenone、Antimycin A组总线粒体、超氧化线粒体明显增加,与对照组比较,差异有统计学意义(P<0.05),TTFA组与对照组比较无明显差异。结论葡萄糖腹膜透析液作用下人腹膜间皮细胞线粒体活性氧产生增加。 Objective To explore the effect of mitochondrial reactive oxygen species (ROS) production in human peritoneal mesothelial cells exposed to glucose-based peritoneal dialysis fluids. Methods HMrSV5 cells (SV40 immortalized hu- man peritoneal mesothelial cell line) were grown in type I collagen-coated dishes in DMEM/F12 containing 10% FCS. All ex- periments on HMrSV5 cells were performed between passage 5 and 10. Cell viability was assessed by MTT. Cells were divided into 7 groups: control group, 1.5%Dextrose group, 2.5%Dextrose group, 4.25%Dextrose group, Rotenone group, Thenoyltrifluo- roacetone (2"TFA) group, Antimycin A group. Flow cytometric was used to analyze the respiring (Mitotracker deep red), total (Mitotracker deep green) and ROS-generating mitochonclria (MitoSOX). Results Treatment for 12h, total and ROS-generat- ing mitochondria were significantly increased in the cells exposed to 1.5%Dextrose group, 2.5%Dextrose group, 4.25%Dextrose group, Rotenone group and Antimyein A group when compared to the control group (P〈0.05), and there was no obvious difference in TTFA group in contrast to control group. Conclusion Glucose-based peritoneal dialysis fluids can increase the mito- chondrial ROS production in human peritoneal mesothelial cells.
出处 《中国现代医药杂志》 2015年第10期5-8,共4页 Modern Medicine Journal of China
基金 国家自然科学基金项目(编号:81200555)
关键词 葡萄糖腹膜透析液 人腹膜间皮细胞 线粒体活性氧 Glucose-based peritoneal dialysis fluids Human peritoneal mesothelial cells Mitochondrial reactive oxy- gen species
  • 相关文献

参考文献18

  • 1Oreopoulos DG, Yang X. Long-term survival on peritoneal dialysis is not a dream anymore:lessons from the East. Perit Dial Int, 2007,27(4) :410-412.
  • 2伍军,阳晓,余学清.腹膜透析与血液透析:哪种透析治疗方式具有更好的生存率?[J].中华肾脏病杂志,2008,24(12):931-933. 被引量:6
  • 3Raha S, Robinson BH. Mitochondria ,oxygen free radicals ,and apoptosis. American Journal of Medical Genetics,2001,106 (1) : 62-70.
  • 4Green K,Brand MD, Murphy MP. Prevention of mitochondrial ox- idative damage as a therapeutic strategy in diabetes. Diabetes, 2004,53(1):110-118.
  • 5Yung S ,Chan TM. Mesothelial cells. Petit Dial Int ,2007,27 Sup- pl 2:110-115.
  • 6Yung S,Chan TM. Intrinsic cells: mesothelial cells central players in regulating inflammation and resolution. Petit Dial Int, 2009,29 Suppl 2 : 21-27.
  • 7Schroder K,Tschopp J. The inflammasomes. Cell,2010,140(6):821-832.
  • 8Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflamma- tory disease reloaded : a clinical perspective. Cell, 2010,140 (6) : 784-790.
  • 9Dostert C ,P6trilli V,Van Bruggen R,et al. Innate immune activa- tion through Nalp3 inflammasome sensing of asbestos and silica. Scienee,2008,320 (5876) : 674-677.
  • 10Wu J, Yang X,Zhang YF, et al. Glucose-based peritoneal dialysis fluids downregulates TLR and triggers hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells. Clinical and Vaccine Immunology,2010,17 (5) :757-763.

二级参考文献31

  • 1Wright CC, Sim J, Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol, 2003, 56: 833-842.
  • 2Xue JL, Chen SC, Ebben JP, et al. Peritoneal and hemodialysis: Ⅰ. Differences in patient characteristics at initiation. Kidney Int, 2002, 61: 734-740.
  • 3Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol, 2003, 14: 415-424.
  • 4Stack AG, Molony DA, Rahman NS, et al. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int, 2003, 64: 1071-1079.
  • 5Lo WK. Peritoneal dialysis utilization and outcome: what are we facing? Perit Dial Int, 2007, 27 Suppl 2: S42-S47.
  • 6Finkelstein FO. Structural requirements for a successful chronic peritoneal dialysis program. Kidney Int Sppul, 2006, (103): S118-S121.
  • 7Burkart J, Piraino B, Kaldas H, et al. Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial, 2007, 20: 200-202.
  • 8U.S. Renal Data System: USRDS 2005 Annual Data Report: Atlas of End- Stage Renal Disease in the United States. Bethesda,MD: National Institutes of Health,National Institute of Diabetes and Digestive and Kidney Disease 2005.
  • 9Sehulman G. Mortality and treatment modality of end-stage renal disease. Ann Intern Med, 2005, 143: 229-231.
  • 10Vonesh EF, Snyder JJ, Foley RN, et al. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int, 2004, 66: 2389-2401.

共引文献5

同被引文献1

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部